We are live on ! Find out more
ARLZ

Aralez Pharmaceuticals Inc.
ARLZ

Delisted

ARLZ was delisted on the 20th of August, 2018.

Back to rankings

63 hedge funds and large institutions have $17.1M invested in Aralez Pharmaceuticals Inc. in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

7% more funds holding

Funds holding: 59 → 63 (+4)

6% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 17

42% less capital invested

Capital invested by funds: $29.6M → $17.1M (-$12.5M)

64% less call options, than puts

Call options by funds: $63K | Put options by funds: $175K

Holders
63
Holders Change
+4
Holders Change %
+6.78%
% of All Funds
1.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
16
Reduced
17
Closed
7
Calls
$63K
Puts
$175K
Net Calls
-$112K
Net Calls Change
-$178K

Top Buyers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
+$679K
2
Goldman Sachs
Goldman Sachs
New York
+$264K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$156K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$136K
5
Millennium Management
Millennium Management
New York
+$108K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.28M
2
PCM
PAR Capital Management
Massachusetts
-$751K
3
CIM
Contrarius Investment Management
Jersey
-$495K
4
Deutsche Bank
Deutsche Bank
Germany
-$451K
5
GCP
GSA Capital Partners
United Kingdom
-$123K
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
1
PAR Capital Management
Massachusetts
$8.44M -$751K -457,691 -7%
DM
2
Deerfield Management
New York
$2.33M – – –
Wells Fargo
3
Wells Fargo
California
$975K +$679K +413,801 +152%
GCP
4
GSA Capital Partners
United Kingdom
$560K -$123K -74,751 -16%
Deutsche Bank
5
Deutsche Bank
Germany
$524K -$451K -274,515 -43%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$443K – – –
JAM
7
JW Asset Management
Florida
$411K – – –
Goldman Sachs
8
Goldman Sachs
New York
$371K +$264K +160,621 +159%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$277K +$156K +95,335 +96%
BMCM
10
Bryn Mawr Capital Management
Pennsylvania
$260K – – –
BAS
11
Brown Advisory Securities
Maryland
$244K – – –
IP
12
Isthmus Partners
Wisconsin
$234K +$6.7K +4,084 +3%
SM
13
Salzhauer Michael
$151K – – –
California Public Employees Retirement System
14
California Public Employees Retirement System
California
$150K – – –
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$150K +$136K +82,898 +368%
FSA
16
Franklin Street Advisors
North Carolina
$137K -$4.6K -2,800 -3%
BP
17
Ballentine Partners
Massachusetts
$137K +$26.6K +16,200 +20%
Macquarie Group
18
Macquarie Group
Australia
$99K – – –
Millennium Management
19
Millennium Management
New York
$93K +$108K +65,770 New
Morgan Stanley
20
Morgan Stanley
New York
$88K +$23K +14,021 +29%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$86K +$10.1K +6,162 +11%
PP
22
Paloma Partners
Connecticut
$85K +$98.4K +59,939 New
Northern Trust
23
Northern Trust
Illinois
$81K +$6.85K +4,174 +8%
PPA
24
Parametric Portfolio Associates
Washington
$78K +$26.7K +16,263 +42%
Janney Montgomery Scott
25
Janney Montgomery Scott
Pennsylvania
$63K +$16.4K +10,000 +29%
1
2 3

ARLZ Hedge Fund Activity: Q4 2017 in Review

63 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q4 2017, worth a combined $17.1M — down 42% from $29.6M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ARLZ positions and 7 closed out — a net gain of 4 holders — while 16 added to existing stakes and 17 trimmed.

The largest buyer was Wells Fargo, adding an estimated $679K. The largest seller was BlackRock, exiting entirely with an estimated $2.28M sold.

  • 63 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q4 2017, up from 59 in Q3 2017.
  • Funds reported $17.1M of Aralez Pharmaceuticals Inc. stock for Q4 2017, down 42% quarter-over-quarter.
  • 11 funds opened new Aralez Pharmaceuticals Inc. positions in Q4 2017 and 7 closed out, a net change of +4 holders.
  • The largest Aralez Pharmaceuticals Inc. buyer in Q4 2017 was Wells Fargo, an estimated $679K added.
  • The largest Aralez Pharmaceuticals Inc. seller in Q4 2017 was BlackRock, an estimated $2.28M sold.

Based on aggregated 13F filings for Q4 2017.